Naglazyme Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The naglazyme market research report is one of a series of new reports that provides naglazyme market statistics, including naglazyme industry global market size, regional shares, competitors with a naglazyme market share, detailed naglazyme market segments, market trends and opportunities, and any further data you may need to thrive in the naglazyme industry. This naglazyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to increasing investment in orphan drug development, growing number of clinical trials, growing medical insurance coverage, rising demand for novel therapies, and increasing number of patients diagnosed with MPS VI globally. Major trends in the forecast period include technological advancements, telemedicine, integrating digital health tools, home infusion therapies, biomarkers, and personalized medicine.

The rising incidence of rare genetic disorders is expected to drive growth in the naglazyme market. Rare genetic disorders are inherited conditions caused by gene mutations, which affect a small segment of the population. The increasing prevalence of these disorders is linked to factors such as genetic mutations, improved genetic testing, and population growth. Naglazyme, an enzyme replacement therapy, provides treatment for rare genetic disorders such as mucopolysaccharidosis VI (MPS VI). It works by breaking down and reducing the buildup of glycosaminoglycans (GAGs), which helps improve mobility, respiratory function, and overall quality of life for affected patients. For example, a 2022 report from the National Library of Medicine highlighted that Gaucher Disease has a birth prevalence of 1.5 cases per 100,000 live births. As the incidence of rare genetic disorders rises, so does the demand for treatments such as naglazyme.

The increasing adoption of personalized medicine is also expected to drive the growth of the naglazyme market. Personalized medicine involves tailoring medical treatments based on an individual's genetic makeup, lifestyle, and environmental factors, aiming for more effective outcomes. Factors such as advancements in genomic research, better diagnostic tools, and growing demand for more targeted therapies are contributing to this trend. Personalized medicine enhances the effectiveness of Naglazyme by customizing treatment plans based on a patient's unique genetic profile and disease characteristics, thereby optimizing the enzyme replacement therapy for conditions such as mucopolysaccharidosis VI (MPS VI). According to the Personalized Medicine Coalition, 16 new personalized therapies for rare diseases were approved by the FDA in 2023, a significant increase from the six approvals in 2022. As personalized medicine continues to grow, it is expected to drive further demand for naglazyme.

The growth in healthcare spending is another factor expected to boost the naglazyme market. Healthcare spending encompasses the total financial resources allocated to medical care, hospital services, medications, research, and infrastructure. This increase is driven by factors such as an aging population, advancements in medical technology, the rising prevalence of chronic diseases, and increased demand for healthcare services. Higher healthcare expenditures support the availability and development of specialized treatments such as Naglazyme, ensuring that patients with rare genetic disorders such as MPS VI have access to the care they need. For instance, a report from the Office for National Statistics in the UK showed that healthcare spending increased by 5.6% from 2022 to 2023, compared to just a 0.9% increase in 2022. The UK's healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023, further fueling the demand for treatments such as naglazyme.

The key company operating in the naglazyme market is BioMarin Pharmaceutical Inc.

North America was the largest region in the naglazyme market in 2024. The regions covered in naglazyme report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the naglazyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Naglazyme (galsulfase) is an enzyme replacement therapy used to treat mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy syndrome. It works by providing the missing or deficient enzyme, which helps reduce the accumulation of glycosaminoglycans (GAGs) and alleviate some of the disease's symptoms. The medication is administered through intravenous infusion, typically under the supervision of a healthcare professional experienced in managing MPS disorders.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indication for Naglazyme is the treatment of maroteaux-Lamy syndrome and other rare lysosomal storage disorders. Maroteaux-Lamy syndrome is a rare genetic condition caused by a deficiency of the enzyme arylsulfatase B. Naglazyme is suitable for both pediatric and adult patients and is distributed through various channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, online pharmacies, as well as government and public health programs. It is used by a variety of end users, such as hospitals, specialty clinics, research institutions, and homecare settings.

The naglazyme market consists of sales of injectable solution and lyophilized powder. Values in this market are ‘factory gate’ values, which represent the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.